As of November 7, 2026, ProQR Therapeutics N.V. is a publicly traded company (Nasdaq: PRQR). The largest holder reporting an active stake on Schedule 13D is Van Herk Investments B.V., at 10.9%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include ELI LILLY & Co (15.6%), Aberdeen Group plc (6.33%), Adage Capital (6.27%) (Schedule 13D/A, July 29, 2026).
Is this your company?
About to sign with, pay or invest in ProQR Therapeutics N.V.? See the free Snapshot first.
Free to see. No signup.
Is ProQR Therapeutics N.V. a real, registered company?
- ProQR Therapeutics N.V. files with the SEC under CIK 1612940 (its SEC filings).
- Its shares are listed under the ticker PRQR on Nasdaq (SEC company record).
- Incorporated in P7, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under ProQR Therapeutics N.V. in our court records and SEC 8-K records (as of 2026-11-07).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Van Herk Investments B.V. (filed 2026-07-29).
Who are ProQR Therapeutics N.V.'s owners and officers?
ProQR Therapeutics N.V.: industry Pharmaceutical Preparations (Schedule 13D/A, 2026-07-29).
| Report | Holder | Share |
|---|---|---|
| Schedule 13D/A, 2026-07-29 | Van Herk Investments B.V. | 10.9% |
| Schedule 13G, 2026-07-29 | Aberdeen Group PLC | 6.33% |
| Schedule 13G/A, 2026-07-24 | Eli Lilly & Co | 15.6% |
| Schedule 13G/A, 2026-07-15 | Patrick Johan Hendrik Krol | 5.2% |
| Schedule 13D/A, 2026-06-30 | Van Herk Investments B.V. | 10.9% |
| Schedule 13D/A, 2026-06-03 | Van Herk Investments B.V. | 14.6% |
| Schedule 13D/A, 2026-02-06 | Van Herk Investments B.V. | 14.6% |
| Schedule 13G, 2026-01-20 | Privium Fund Management B.V. | 5.2% |
| Schedule 13D/A, 2025-09-30 | Van Herk Investments B.V. | 13.6% |
| Schedule 13D/A, 2025-09-04 | Van Herk Investments B.V. | 12.6% |
| Schedule 13D/A, 2025-08-20 | Van Herk Investments B.V. | 11.6% |
| Schedule 13G/A, 2025-08-12 | Adage Capital Management, L.P. | 6.27% |
Questions about who owns ProQR Therapeutics N.V.
Who owns ProQR Therapeutics N.V.?
On this page, 6 holders' latest ownership filings report 5% or more of ProQR Therapeutics N.V.: Eli Lilly & Co (15.6%, Schedule 13G/A, filed 2026-07-24), Van Herk Investments B.V. (10.9%, Schedule 13D/A, filed 2026-07-29), Aberdeen Group PLC (6.33%, Schedule 13G, filed 2026-07-29), Adage Capital Management, L.P. (6.27%, Schedule 13G/A, filed 2025-08-12) and Patrick Johan Hendrik Krol (5.2%, Schedule 13G/A, filed 2026-07-15); 1 more is listed above.
Who are the largest shareholders of ProQR Therapeutics N.V.?
By the share each holder's latest filing reports, the largest holders of ProQR Therapeutics N.V. on this page are Eli Lilly & Co (15.6%), Van Herk Investments B.V. (10.9%) and Aberdeen Group PLC (6.33%).
When did Eli Lilly & Co buy into ProQR Therapeutics N.V.?
The filings give report dates, not purchase dates. The earliest filing from Eli Lilly & Co on this page is the Schedule 13G/A, filed 2026-07-24, reporting 15.6%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on ProQR Therapeutics N.V.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on ProQR Therapeutics N.V.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on ProQR Therapeutics N.V. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own ProQR Therapeutics N.V. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief scientific officer and a director: 824,388 shares (0.78% of shares outstanding) (Form 3, 2026-03-18).
- , a director: 725,692 shares (0.69% of shares outstanding), 420,729 held directly and 304,963 indirectly (Form 3, 2026-03-18).
- , the chief executive and a director: 500,000 shares (0.47% of shares outstanding) (Form 4, 2026-08-03).
- , a director: 300,000 shares (0.28% of shares outstanding) (Form 4, 2026-07-21).
- , a director: 61,538 shares (0.06% of shares outstanding) (Form 3, 2026-03-18).
Shares outstanding: 105,361,064 as of 2025-12-31, from the company's latest SEC cover page.
How much has ProQR Therapeutics N.V. raised?
No fundraising or offering filing from ProQR Therapeutics N.V. is on file with us.
Keep reading
More on ProQR Therapeutics N.V. and the records around it.
ProQR Therapeutics N.V. elsewhere on the record
- 5%+ stake filings Jul 2026
Companies that share a holder
- ELI LILLY & Co also filed stake reports on 5 other companies: TRex Bio, Inc. (Oct 2026), Scribe Therapeutics, Inc. (Jul 2026), Ionetix Corp / DE / (Jul 2026)
- Aberdeen Group plc also filed stake reports on 12 other companies: Equillium, Inc. (Nov 2026), IMMUNIC, INC (Nov 2026), CODEXIS, INC. (Oct 2026)
- Adage Capital Management, L.P. also filed stake reports on 136 other companies: ACP Holdings Acquisition Corp. (Aug 2026), AmperCap Acquisition Company (Aug 2026), Aura Biosciences, Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/proqr-therapeutics-nv